Drug Type TCR therapy |
Synonyms Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen, KSH 01, KSH01 |
Target |
Mechanism MAGEA4 inhibitors(Melanoma-associated antigen 4 inhibitors), Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 1 | CN | 11 Oct 2022 | |
Esophageal Carcinoma | Phase 1 | CN | 11 Oct 2022 | |
Melanoma | Phase 1 | CN | 11 Oct 2022 | |
Stomach Cancer | Phase 1 | CN | 11 Oct 2022 | |
Relapsed Solid Neoplasm | Phase 1 | CN | 19 Aug 2022 | |
Advanced Malignant Solid Neoplasm | IND Approval | CN | 26 Apr 2024 |